ACIP Upheaval Leaves Merck & Co. In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products expected to be recommended for use by the CDC Advisory Committee on Immunization Practices later this month.

Merck's CEO still expects the June ACIP meeting to take place as scheduled despite all of the committee members being removed. (Shutterstock)

More from Vaccines

More from Agency Leadership